Advances in Brief

Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas

Waldemar Debinski, Denise M. Gibo, Stanley W. Hulet, James R. Connor, and G. Yancey Gillespie

Section of Neurosurgery, Department of Surgery [W. D., D. M. G.], and Department of Neuroscience and Anatomy [S. W. H., J. R. C.], Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033-0850; and Division of Neurosurgery, Department of Surgery, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294-0006 [G. Y. G.]

Abstract

Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor-specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this receptor produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

Introduction

GBM is a rapidly progressive human high-grade glioma for which no effective treatment is available, and the incidence of brain tumors is on the rise (1, 2). It has been a continuous and, so far, unsuccessful challenge to uncover a receptor for a growth factor/cytokine or an antigen that is not present in normal tissues to any significant degree but is present in >50% of patients with high-grade gliomas, such as GBM. Due to the morphological heterogeneity of GBM tumors, it seemed exceedingly difficult to identify such a potential diagnostic, imaging, therapeutic target receptor, or antigen.

We previously found large amounts of a receptor for IL-13 on a majority of the established human malignant glioma cell lines studied (3) and on cells cultured from freshly resected GBM (4). IL-13 regulates immune responses in a similar manner to its homologue, IL-4 (5, 6), and shares a functional signaling IL-13R/IL-4R that is present on selected normal tissues and is overexpressed on some adenocarcinomas (7–9).

The potential importance of a cancer-associated receptor/antigen depends exclusively on its tumor representation versus expression in normal tissue in situ. It is noteworthy that recent studies on GBM showed either that a clinically present antigen of high specificity is completely lost in cell culture (10) or that, in a reverse scenario, overexpression of an intracellular molecule seen in vitro does not correspond to an in situ situation (11). Therefore, the demonstration of the presence of hIL-13 binding sites in GBM and the absence of them on normal brain tissues, using freshly preserved surgical specimens, was essential in substantiating a possible clinical importance of the in vitro-detected candidate marker/target (3). This work demonstrates an unexpected discovery of an extraordinarily rich presence of the IL-13R in human GBM but not in normal brain.

Materials and Methods

Production and Purification of Recombinant Proteins. Escherichia coli BL21 (λDE3) cells were transformed with plasmids of interest and cultured in Terrific Broth (Difco Laboratories, Detroit, MI). Procedures for recombinant proteins isolation and purification have been described previously (3, 7, 12).

Autoradiography. Recombinant hIL-13 (7) was labeled with 125I by using the Iodo-Gen reagent (Pierce Chemical Co., Rockford, IL) according to the manufacturer’s instructions. The specific activity of 125I-hIL-13 ranged from 40 to 852 μCi/μg of protein. Six different batches of labeled hIL-13 were used in this study. All studies involving human specimens were approved by the respective Human Subjects Protection Offices at the Penn State College of Medicine (Protocol No. IRB 96–123EP) and University of Alabama Medical School. Normal human brain tissues were obtained either from lobectomies and snap-frozen for analysis or they were obtained postmortem from the Harvard Brain Tissue Research Center. GBM tumor samples were obtained from the operating rooms in Penn State College of Medicine and University of Alabama Medical School. Among the 23 patients evaluated, there were 12 females and 11 males, varying in age from 16 to 79 years. The GBMs obtained from a
Results

To demonstrate the presence of IL-13-binding sites in clinical specimens in situ, we performed autoradiography with radiolabeled recombinant hIL-13 (Fig. 1, A–C). Twenty-two of 23 adolescent/adult GBMs studied bound 125I-hIL-13, and an excess of unlabelled hIL-13 competed for the binding in all these tumor specimens. The GBM tissues generally labeled densely and homogeneously for 125I-hIL-13-binding sites (Fig. 1, A–C). An excess of recombinant hIL-4 was largely without influence on the 125I-hIL-13 binding to the specimens (Fig. 1, A–C). This is in line with our in vitro observations of a hIL-4-independent GBM-associated hIL-13R (3, 4), and it demonstrates that the clinical GBM-associated hIL-13R is different from the functional hIL-13R/hIL-4R (8, 9) of normal tissue. The GBM specimen 6 (Fig. 1A) bound 125I-hIL-13, but its binding was competed for by a cold competitor over the limited area of the section. Only GBM 20 did not show any uptake of the isotope. GBMs 11 (Fig. 1C) and 15 had relatively lower binding of hIL-13 when compared with other GBMs, but it was specific for hIL-4.

In another test of specificity of the hIL-13 binding to GBM, we used Tf in an attempt to displace the binding of radiolabeled IL (Fig. 1, A and B). We did not observe cross-competition of Tf with the hIL-13-binding sites in the five GBMs examined (Fig. 1, A and B). Thus, the autoradiographic analysis revealed an extraordinary high number of GBMs that express abundantly the more restrictive, IL-4-independent binding sites for IL-13. In another set of experiments and test of specificity, GBM did not exhibit any measurable overexpression of the receptor for hIL-4.

To visualize the areas of GBM sections that bind the labeled hIL-13, we examined the autoradiograms by light microscopy and with epifluorescence optics. As seen in Fig. 1D, 125I-hIL-13-specific binding was distributed relatively uniformly over the whole area of the GBM specimens. Light microscopic analysis revealed that the vast majority of tumor cells was stained with silver grains. This strongly supports the notion that majority of GBM cells possess this more restrictive IL-13R in situ.

Because only 1 of the 23 evaluated adolescent/adult GBMs lacked 125I-hIL-13 binding and few more had relatively heterogeneous binding, we analyzed H&E-stained sections that corresponded to all of the autoradiographic images. Those areas of the GBM samples that did not show specific binding of 125I-hIL-13 or that demonstrated more heterogeneous binding were completely (e.g., GBM 20) or partially (e.g., GBM 6) acellular/necrotic. The GBM specimens that bound 125I-hIL-13 avidly had the tumor cellular organization preserved. Thus, it is plausible that all GBMs overexpress hIL-13R. In preliminary studies, other types of brain tumors, including lower-grade gliomas, menigiomas, and medulloblastomas, did not demonstrate this pattern of hIL-13 binding to GBM.

In sharp contrast to the results obtained in GBM, none of the normal human brain tissue samples did reveal appreciable affinity for 125I-hIL-13 (six specimens are shown in Fig. 2). All of the examined specimens showed the same low retention of the 125I-hIL-13 when compared with the labeling of

Fig. 1  A–C, autoradiographic demonstration of the binding sites for $^{125}$I-hIL-13 on human GBM and the specificity of this binding in the presence of an excess of either unlabeled hIL-13 or hIL-4 or Tf. The numbering of tumor specimens corresponds to the order of their autoradiographic examination. A, films were exposed from 7 to 9 days, except for GBM 7, which was exposed for 11 days. B, histogram of the scanning of the binding of $^{125}$I-hIL-13 to GBM specimens, as shown in A. Patients’ ages (numbers)/sexes (M/F) are given below the GBM specimen number. C, films were exposed for 3 days, except for: GBM 13, 16, and 19, which were exposed for 16 h; GBM 18, which was exposed for 8 h; GBM 21, which was exposed for 5 days; and GBM 23, which was exposed for 6 days. D, digitized epifluorescence image of the specific binding of $^{125}$I-hIL-13 to GBM specimens. The bottom right corners are empty of tissue.
GBM, and this low-level binding was changed only marginally, if any, in the presence of an excess of either hIL-13 or hIL-4 (Fig. 2). Overexposed films confirmed the same pattern. These results provide more evidence that the IL-4-independent hIL-13R that we have detected on GBM is absent or is at negligible levels in normal brain and, thus, is a tumor-specific marker. This in line with the lack of or negligible effect of the hIL-13-based CTX on normal cells, such as HUVECs (12, 14). A similar lack of susceptibility to a hIL-13-CTX was seen in freshly cultured mixed glial cells. Not surprisingly, however, a CTX that targets Tf receptor did kill HUVECs potently at an IC50 of ~10 ng/ml. This is in a range of killing potency of the anti-Tf receptor-CTX observed on some glioma cells in vitro. Normal endothelial cells contribute significantly to the strong autoradiographic picture of Tf-binding sites within normal brain (15). The IL-4-CTX also potently killed HUVECs (IC50 of ~25 ng/ml), which is in line with at least two orders of magnitude higher affinity of IL-4 toward the hIL-13R/hIL-4R, compared with IL-13 (16).

In addition to the diagnostic and/or imaging importance of our findings, we explored their relevance to therapeutic applications. We showed that a CTX that targets the hIL-13R could produce dramatic antitumor effects in vivo. We used i.t. injections of the CTX because: (a) i.t. delivery has recently been shown to be a promising approach in the treatment of central nervous system malignancy (17–19) and (b) the s.c. model of GBM in mice was predictive of good clinical responses using targeted CTXs (18, 20). Because IL-13, unlike IL-4, is not species specific, the mouse model chosen in this study is even more representative of a clinical situation. We treated mice bearing established s.c. xenografts of U-373 MG glioma with either the vehicle or a hIL-13-CTX (Fig. 3A). The treatment started on day 80 post-tumor implantation when the tumors were ~200 cmm in size (8 × 8 × 8 mm). We found that five i.t. injections of 0.5 μg of the hIL-13-CTX every other day produced complete regression of the U-373 MG tumors in all of the CTX-treated mice with no signs of toxicity, and one mouse remained free of tumor in the 0.1-μg CTX-treated group (Fig. 3A). In a faster growing U-251 MG tumor model, when similar in size to U-373 MG tumors were detected on day 30, six i.t. injections of 0.5 μg of the CTX every other day cured (100 days tumor free) 60% of treated mice. Significantly, the treatment of established intracranial U-251 MG tumors resulted in a highly significant prolongation of the survival of mice, and >40% of the mice were cured (Fig. 3B).

Discussion

The main finding of this study is that all nonnecrotic/well-preserved surgical specimens of human GBMs overexpressed specific binding sites for 125I-hIL-13 in situ, whereas normal human brain tissue sections did not. Significantly, 125I-hIL-13 binding to brain tumor tissues was not blocked with hIL-4. This ascertains that the GBM-associated hIL-13R is different from the functional IL-13R/IL-4R expressed by some normal hematopoietic and somatic cells (8, 9). The tumor-associated hIL-13R appears to be stable and abundantly expressed in GBM because both explant cells (4) and established tumor cell lines (3, 4) exhibit significant levels of the receptor. This offers a unique experimental scenario in which a receptor that is overexpressed in vitro corresponds to the frequency and form of the receptor that is found clinically. The expression of an IL-4-independent hIL-13R by GBM cells has been shown by us to be of significance for further translation of this finding into clinical applications (12, 14). Furthermore, the hIL-13-based CTX showed curative activities in both s.c. and intracranial models of human glioma. Thus, a profound effect of the glioma cells environment on their biological behavior (21) did not largely influence the outcome of therapy with a hIL-13 CTX.
It is intriguing that an immune regulatory cytokine receptor is so richly represented in GBM. This linkage between transformation of brain glial cells, the cells believed to be the origin of GBM, and expression of an anti-inflammatory cytokine receptor is unclear at present. However, it has been amply shown that normal glial cells can function in an immune-related capacity in the central nervous system (22). Moreover, a growing body of evidence clearly demonstrates that a wide variety of immune-related cytokines and their cognate receptors are expressed to some extent by human malignant glioma cells (23, 24).

In summary, the GBM-associated hIL-13R represents a unique new marker for diagnostic labeling of cells and potentially for imaging and a target for delivery of cytotoxic or cytostatic therapies to this most devastating malignancy. Our study supports the idea that a malignancy as heterogeneous as glioma could, indeed, be characterized by the expression of specific molecules (25–27). Further investigations based on the knowledge of those molecules should help also in deciphering the pathogenesis of GBM.

References


Fig. 3 Antitumor activity of a hIL-13-CTX on s.c. human xenografts of the U-373 MG glioma tumors growing in athymic mice (A) and intracranial human xenografts of the U-251 glioma tumors growing intracranially in severe combined immunodeficiency mice (B). Arrowheads (A), days of either vehicle (PBS-0.1% BSA) or CTX injections at 0.1 and 0.5 μg per mouse in a final volume of 25 μl. Data points, tumor volumes calculated for four to five mice per group; bars, SEs. The vehicle-treated animals were sacrificed due to the large tumor burden.


Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas

Waldemar Debinski, Denise M. Gibo, Stanley W. Hulet, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/5/5/985

Cited articles
This article cites 24 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/5/5/985.full#ref-list-1

Citing articles
This article has been cited by 26 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/5/5/985.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/5/5/985.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.